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INTRODUCTION
Gastric carcinoma is the fourth most commonly diagnosed cancer
in the world and is the second leading cause of cancer related death. In
the West, the incidence is spontaneously declining for unknown reasons.
In Asia it is still one of the commonest cancers accounting to around 13%
of all malignancies. In countries like Japan and Korea in Eastern Asia, it
accounts for 56% of all malignancies. Early diagnosis is challenging
because of absence of symptoms in this stage of disease. More than
50% of patients with gastric cancer present in advanced, unresectable
stages, making cure impossible. Two-thirds of these patients who
undergo radical surgery will experience. Systemic treatment is the only
option for the patients presenting in advanced stages. The median
survival after diagnosis of metastatic disease is approximately 10-11
months with currently available therapies. Despite the introduction of
multimodality treatment, neoadjuvant chemotherapy, postoperative
chemoradiation and new chemotherapeutic regimens, there is only a
minimal impact on the relapse free survival and overall survival of these
patients. Many single agents and combination chemotherapeutic agents
are active in the treatment of metastatic disease. Objective response rates
ranging from 10% to 30% for single-agent and 30% to 60% for
combination regimens have been reported. Although a large number of
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chemotherapy regimens are available, there is still no internationally
accepted standard of care. Survival of patients presenting with advanced
gastric cancer is still only 4%-10% at five years. Newer therapies are
urgently needed for their better outcome. Recently, understanding of the
molecular basis of cancer has contributed to the development of
rationally designed molecular targeted therapies, which interfere with
signalling cascades involved in cell differentiation, proliferation, and
survival, of which EGFR plays an important role. Trastuzumab is one of
the targeted drugs against EGFR2 (commonly known as HER-2/neu) and
has recently shown to increase survival in patients with metastatic gastric
carcinoma when given along with combination chemotherapy.
Recent evidence suggests that patients diagnosed with metastatic
gastric cancer should have the HER-2/neu status of their tumors to get
benefit from treatment with Trastuzumab in combination with
chemotherapy in case of HER-2/neu positivity. We conducted this study
to analyse the prevalence and significance of HER-2/neu over expression
in patients with gastric carcinoma.
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REVIEWOF LITERATURE
Over 870,000 cases of stomach cancer diagnosed each year. (1,2)
It is more common in Eastern Asia where it accounts for more than 50%
of all malignancies. It is rare in European countries and America. In India
Gastric cancer is the fifth most common malignancy in males and
seventh most common in females.(3) The highest incidence in India is in
Mizoram where it accounts for nearly 30% of all newly detected cancers.
The reason for this increase is thought to be genetic and dietary factors
although the exact reason is not understood. In the Madras Metropolitan
Tumor Registry, carcinoma of stomach ranks second from top among
males and fifth among females in crude incidence rate.
In Asian population most of the malignancies are in the distal
stomach where as in the West it is more in the proximal stomach.(4) At
the time of diagnosis, gastric cancers are localized and surgically
resectable in approximately one half of the patients. Regional nodal
metastases or direct infiltration of surrounding organs or structures are
frequently encountered and preclude cure in many patients. Although
relapse after complete surgical resection occurs most commonly in the
tumor bed and nodal regions, systemic pattern of relapse is also known to
occur commonly in gastric cancer.(5) The overall 5-year survival rate of
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all people with stomach cancer is only about 28% irrespective of the
stage at presentation.
ETIOLOGICAL FACTORS
Etiological factors for gastric cancer include smoked or salted
foods, foods contaminated with aflatoxin, low intake of fruits and
vegetables, low socioeconomic status, and possibly a decreased use of
refrigeration.(6) Possible occupational relationships include coal mining
and rubber or asbestos industry.
PRE MALIGNANT LESIONS
Precursor neoplastic conditions include pernicious anemia,
achlorhydria, atrophic gastritis, gastric ulcers, and adenomatous polyps.(8)
Between 5% and 10% of individuals with pernicious anemia
subsequently develop malignancy. Prior partial gastrectomy for benign
gastric or duodenal ulcer disease produces an increased risk of
subsequent malignancy in the gastric remnant with latency periods of 20
years or more. Helicobacter pylori infection has been shown to
predispose to a three- to six fold increased risk of gastric cancer, but the
precise role of this bacterium in the etiology of gastric cancer remains
unknown.(7) H.pylori is associated mainly with distal and intestinal-type
of gastric cancers.
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GENETICSUSCEPTIBILITY
Some individuals are at increased risk of developing gastric
cancer, because of dominantly inherited cancer predisposition
syndromes, such as Familial adenomatous polyposis, Lynch syndrome,(9)
and Li-Fraumeni syndrome.(10) Patients with Peutz-Jeghers are also at
risk for developing gastric cancers. (11)
Germline mutations in the E-cadherin gene (CDH1) account for
30-40% of Heriditary Diffuse Gastric Cancer.(12) In these patients, the
lifetime risk of developing a gastric cancer is about 67% in men and
83% in women.
SITE OF TUMOR
The site of origin of tumor within the stomach has changed over
recent decades, with more proximal lesions now being diagnosed and
treated. The largest percentage of gastric cancers still arises within the
antrum or distal stomach (around 40%), are least common in the body of
the stomach (around 25%), and are of intermediate frequency in the
fundus and esophagogastric junction (around 35%).
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PATHOLOGY
Two distinct histologic types of gastric cancer, the “intestinal type”
and “diffuse type”, have been described by Lauren.(13) The diffuse type of
gastric cancer is undifferentiated and is characterized by the loss of E-
cadherin expression; an adhesion protein that helps maintains cellular
organization. The well differentiated intestinal type is sporadic and
highly associated with environmental exposures, especially H. pylori
infection.(14) There are also biologic differences between these subtypes
of gastric cancer that may guide treatment strategies. Overexpression of
HER2 is associated with intestinal-type gastric carcinomas more
frequently than diffuse type due to unknown reasons. (15)
PROGNOSTIC FACTORS
The most meaningful prognostic indicators relate to extent of the
disease which is otherwise the stage of the disease. The prognostic
factors are as follows-
1. Presence of peritoneal disease.
2. Number and location of lymph nodes.
3. Adjacent organ infiltration.
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 Prognosis is generally worse with higher grade and diffuse-type
carcinomas, which usually present with higher pathologic stages of
disease but none of these are independent prognostic variables. The 5-
year survival rates for gastric cancer, by stage are as follows:
Stage IA 71%
Stage IB 57%
Stage IIA 45%
Stage IIB 33%
Stage IIIA 20%
Stage IIIB 14%
Stage IIIC 9%
Stage IV 4%
These are well known prognostic factors. Recently evidence also
exists that overexpression of HER-2/neu in gastric cancer is a new,
independent prognostic factor for overall survival.(16,17)
PREDICTIVE FACTORS
There has not been any predictive marker for survival in gastric
cancer patients until molecular studies were done. HER-2/ neu gene is
one of the molecular markers which is usually overexpressed in breast
cancer patients. Recently molecular studies have shown that HER-2/ neu
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geneis also overexpressed in 20-25% of patients with gastric cancer and
treatment with HER-2/ neu antibody has shown to improve survival in
HER-2/ neu overexpressed patients when given along with
chemotherapy. This is the only known predictive factor in carcinoma
stomach. Its role as prognostic factor is yet to be determined. (18)
EPIDERMAL GROWTH FACTOR RECEPTORS
Within a multi-cellular organism, regulation and organization
require biological signals to be transmitted from one cell to another,
across cell membranes. Such is the case with growth factors, which
originates at one site in an organism and needs to be distributed
throughout the organism to many cell types in order to exert their
pleiotropic effects. Systems have evolved to allow a soluble signals like
growth factor to be conveyed from the extracellular space in to the
cytoplasm and nucleus of a cell, thus directing protein synthesis, cellular
growth, and proliferation. Growth factors appear to induce aggregation of
their receptors, leading to activation of these receptors and signal
propagation across the membranes. If unregulated, however, these
growth signals have the potential to promote inappropriate proliferation.
Receptor aggregation in the absence of signal represents unregulated
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growth factor receptor activity which is postulated to occur in human
neoplasia.
Erb B receptors are expressed in various tissues of epithelial,
mesenchymal and neuronal origin, where they are involved in controlling
diverse biological processes such as proliferation, differentiation,
migration and apoptosis. Their expression is deregulated in many types
of human cancer. Owing to the importance of Erb B proteins in cellular
transformation and development, a lot of attention has been focused on
this family of receptor tyrosine kinases. (19)
The EGFR family of trans membrane receptor tyrosine kinases is
composed of four members: HER- 1 also known as erb B 1, HER-2 also
known as erb B2 , HER- 3 also known as erb b3, and HER -4 also termed
erb B4. The molecular structure of the receptor consists of an
extracellular binding domain, a short transmembrane domain and an
intracellular domain with tyrosine kinase(TK) activity except for HER-3
data. (20)
Driven by the binding specificities of the bivalent, epidermal
growth factor related peptide ligands and the complement receptor
available on the cell, Erb B receptor form homodimeric and
heterodimeric complexes. All pair wise combinations of the four
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receptors can be induced by ligands generating a potential for signal
diversification. Alternatively receptor over expression promotes
spontaneous receptor dimerization in the absence of a ligand and
constitute receptor activation.(21)
Binding of the ligand, neuregulin, to HER-3 allows for hetero
dimerization with HER-2 and subsequent transphosphorylation.
Activated HER-3 is capable of activating downstream pathways, and in
particular, is a potent activator of phosphatidylinositol-3- kinase
(PI3K)/Akt pathways. HER-2/neu receptor must homodimerize (ligand-
independent dimerization) or heterodimerize with another member of the
EGFR family, such as HER-3 or HER-4 (ligand-dependent dimerization)
to undergo activation, autophosphorylation, and triggering of the
downstream signaling cascade. Crystal structure studies of HER-2
receptor have revealed fixed conformation resembling ligand activated
state, capable of interacting with other EGFR family members in the
absence of direct ligand binding. HER-2 can enhance signalling by
forming a heterodimer with HER-3, where this has been reported to be
the most mitogenic dimer. (21)
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 ErbB2 receptor heterodimerization also results in signal
diversification, activation of STAT transcription factor is also triggered
by ErbB2 / Erb B4 induced heterodimerisation.
SIGNALING KINETICS-
The cell employs several mechanism to re-establish its default
setting after ligand induced RTK activation. These mechanisms include
receptor dephosphorylation by tyrosine phosphates, receptor
desensitisation by phosphorylation of specific serine and threonine
residues and final receptor downregulation by internalisation and
subsequent lysosomal degradation of the receptor.
HER-2/neu over expression also leads to increased activity of HIF
(hypoxia inducible factor) and subsequently increased VEGF (Vascular
Endothelial Growth Factor) expression in these cells. Overexpression of
HER-2/neu receptor also led to the increase in the basal level of VEGF
secretion in these cells. Subsequent exposure to hergulin led to further
induction of VEGF secretion .These findings indicate that the HER-2/neu
system is an important target for direct and indirect therapy for cancer
and clinical trials of this approach of inhibiting HER-2/neu are currently
ongoing.
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HER-2/neu TESTING IN GASTRIC CANCER IS NECESSARY DUE
TO THE FOLLOWING REASONS
• HER-2/neu gene amplification and HER-2/neu protein over
expression have been observed in various solid tumors other than
breast, including gastric carcinomas. (22-27)
• The rate of HER-2/neu positivity in advanced gastric cancer is
comparable to that seen in locally advanced and metastatic breast
cancer using validated methodology, the large sample set from the
ToGA trial revealed a HER-2/neu positivity rate of 22% in
advanced Gastric carcinoma. (28)
• HER-2/neu has predictive value in gastric cancer. (18)
As in breast cancer, accurate HER-2/neu testing is essential to
identify patients who may benefit from treatment with HER-2/neu
targeted therapy
THE METHODS BY WHICH HER2 STATUS CAN BE ASSESSED
1. IHC- Immunohistochemistry.
2. FISH – Fluroscent in situ hybridisation
3. CISH – Chromogenicn in situ hybridisation
4. SISH –Silver in situ hybridisation
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 Though so many methods are there only IHC and FISH are
validated and IHC is the most common method use to assess HER-2/neu
status.(29)
Guidance for determining HER2 status in gastric cancer.
• IHC and FISH test kit reagents are identical to the breast cancer
HER-2/neu assay systems in terms of reagents, antibodies and
probes.
• Bright-field techniques (IHC) should be used as the primary testing
modality as they allow identification of small tumour foci with
HER-2/neu overexpression within heterogeneous tumour tissue
• Accurate HER-2/neu testing in gastric cancer is dependent on
adherence to the modified IHC scoring system described by
Hofmann et al 2008. (30)
• Highly experienced pathologists are required for accurate
determination of HER-2/neu status and nuances between breast
and gastric tissues.
The methods by which IHC can be done are
1. Hercep test (Dako cytomation)
2. CONFIRM anti her2 (Ventana)
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 IHC can be performed on the tissues obtained after radical surgery
or with even a small tissue obtained by endoscopic biopsy. The
interpretation of HER-2/neu in gastric cancer by IHC is being
standardized and a consensus on reporting HER-2/neu positivity by IHC
has been arrived at recently. While interpreting the points to be followed
are:
• Tumour cells showing either complete, basolateral or lateral
membrane staining should be scored.
• Cytoplasmic staining should never be included when interpreting
results.
• Normal epithelial cells should never be scored
• Artefacts may give rise to false positive interpretation
Modified scoring system by Hoffmann et al 2008 is adhered to
when IHC is done.
The parameters used for IHC scoring in gastric carcinoma are as follows-
1. Intensity of reactivity- such as “absent”, “faint”, (weak),
“moderate”, or “ strong.”
2. Pattern of membrane staining- complete membrane staining was
not necessary; instead even basolateral and lateral staining are
considered positive.
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3. Number of positive cells- at least 10% of the cells in surgical
specimen stained or single cluster of cells in biopsy specimen are
considered positive if adequate intensity is present.
Scoring criteria in surgical specimen
Score 0 No reactivity or membranous reactivity in less than 10%
of the cells.
Score 1+
Faint membranous reactivity in less than or equal to10%
of the cells, cells are reactive only in part of their
membrane.
Score 2+ Weak to moderate complete ,basolateral or lateral
membranous reactivity in more than 10% of the cells.
Score 3+
Strong complete,basolateral or lateral membranous
reactivity in more than 10% of the cells.
Scoring criteria in Biopsy specimen
Score 0
No reactivity or membranous reactivity in any of the
tumor cell.
Score 1+
Tumor cell cluster with faint or barely perceptible
membranous reactivity irrespective of the percentage of
cells stained.
Score 2+
Tumor cell cluster with Weak to moderate complete,
basolateral or lateral membranous reactivity irrespective
of percentage of tumor cells stained.
Score 3+
Tumor cell cluster with strong complete ,basolateral or
lateral membranous reactivity irrespective of percentage
of tumor cells stained.
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HER2Overexpression assessment by IHC
Score 0 Negative
Score 1+ Negative
Score 2+ Equivocal
Score 3+ Positive
Interpretation of IHC
Incomplete membrane positivity
In gastric cancer, lateral membranous staining with linear staining
at contact sites between 2 cells or basolateral membranous staining
creating a U-shaped staining pattern is observed. This is due to the higher
frequency of glandular formations with the lumen in gastric cancer
(intestinal type) wherein basolateral (non luminal) membranes are
stained. The basolateral staining pattern is probably secondary to the
absence of growth factor receptors in the luminal part of the cell. This
incomplete membrane positivity would be considered negative in IHC
HER-2/neu scoring in breast cancer, but should be considered positive in
gastric cancer. The requirement for complete membranous staining is
thus omitted in gastric cancer. (31)
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Heterogeneity
In contrast to breast cancer where IHC for HER-2/neu is usually
homogenous, tumour heterogeneity is more common in gastric cancer.
Heterogeneous staining can sometimes be seen within one gland. The
most important reason for heterogeneous staining, however, is that up to
one third of gastric cancers are of mixed intestinal/diffuse type. Strong
staining is often seen in areas of an intestinal type of differentiation,
while areas of diffuse types of differentiation are negative. (34) Signet ring
cell carcinomas are almost always negative. An identical heterogeneous
pattern of staining is identified at the DNA level (amplification). Because
of heterogeneity, the 10% cut-off level for positivity, which is required in
breast cancer, is omitted in gastric cancer. Positivity in gastric cancer
specimens is thus independent of the percentage of stained cells and it is
sufficient to have a cohesive group of cells displaying HER-2/neu
positivity. The heterogeneity of HER-2/neu overexpression / amplication
is difficult to explain from the biologic point of view the mechanisms
leading to silencing HER-2/neu expression in an area of a tumor with
homogeneous HER-2/neu amplification, is at present unknown.(32)
FISH
Gene amplification assessment is done by FISH. It is commonly
done when IHC results are 2+ for confirmation of HER-2/neu positivity.
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AHER-2/neu:CEP17 (centromeric probe 17) ratio of >2.2 is now used to
define HER-2/neu positivity (amplification). Ratios of 1.8–2.2 to define
equivocal and <1.8 are used to denote negative categories. FISH is not
routinely used for testing, because it is a difficult, cumbersome and
expensive technique that requires trained personnel which is not available
in every pathology laboratory. Moreover, fluorescence fades upon
storage for a long time thus making it difficult to preserve the slides for
further reference if needed. In addition, the fluorescent probes in the kits
have a limited half life. Detailed morphological features of the tumor are
also usually difficult to observe due to the required protein digestion and
the fluorescent mode, and heterogeneity can be missed since spots are
evaluated at ×100 magnification using oil immersion. (33)
During endoscopy, as many biopsies as possible must be taken
from the area suspicious for cancer. It is recommended to take at least 6
biopsies to increase the results Biopsies as well as surgical specimens can
be used for HER2 testing with similar success rates. Indeed, the
percentage of positivity is not statistically different for biopsies (22.8%)
and surgical samples (20.0%) in the ToGA trial.(34)
The concordance between IHC and FISH is more than 95%. The
other methods which can be used for testing HER-2/neu are CISH and
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SISH. Prediction of HER-2/neu status by imaging mass spectrometry is
based on the molecular alteration brought about by its over expression.
This will enable us to detect unique molecular and genetic alterations that
are independent of site of tumor and may be targeted with drugs. (35)
CONCORDANCE BETWEEN PRIMARY AND METASTATIC
SITES
When HER-2/neu status was assessed by IHC and FISH on
samples obtained from metastatic sites of gastric carcinoma and paired
primary tumors, to establish whether treatment decision with anti HER-
2/neu can be taken by assessing it in the metastatic tissue if easily
accessible, it was found that there was 95% concordance of receptor
expression between primary and metastatic site. Thus in patients in
whom metastatic sites are easily accessible HER-2/neu status can be
studied from these lesions and treatment started accordingly.(36)
Expression of TOP II ALPHA gene
When patients who were HER-2/neu positive were tested for TOP
II alpha, two thirds of them showed co-amplification of TOP II gene.
This suggests that majority of the patient who are HER-2/neu positive
will respond to Top II inhibiting drugs. This is in line with clinical
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findings and topII inhibitors Adriamicin and Etoposide are widely used
cytotoxic drugs in treating gastric cancer.(37,38)
CLINCO PATHOLOGIC CHARACTERISTICS ASSOCIATED
WITH HER-2/neu OVEREXPRESSION
Clinicopathological data was obtained from patients who had
undergone surgical resection for histologically proven gastric cancer
representing the entire population of surgically operable gastric cancer
patients at different institutions who had given consent for research by
the results were analysed statistically against available
clinicopathological criteria-gender, age, tumour size, tumour stage,
histological grade, vascular invasion, perineural invasion, lymphatic
invasion and survival time. Survival was measured from the date of
diagnosis until the date from death from gastric cancer, or was censored
until the date of the last follow-up for non-gastric cancer related deaths
and survivors). No significant relation was found between
clinicopathologic variables (sex and age of the patients, and tumor
diameter, differentiation, location) (39,40)
HER-2/neu status was correlated with the depth of invasion, TNM
stage, lymph node and distant metastasis (P<0.05). No significant relation
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was found between clini-copathologic variables (sex and age of the
patients, and tumor diameter, differentiation, location) (41)
HER-2/neu positivity differed significantly by histological subtype
(intestinal 34%, diffuse 6%, mixed 20%) (42) and according to the site of
the tumor (32% GEJ and 18% gastric localization). A higher rate of
HER-2/neu positivity was seen in GEJ tumors than in gastric cancer
samples (34% vs 20%). The reasons quoted for high positivity were the
association of this oncogene with a specific histologic tumor type and
that certain characteristics (e.g. HER-2/neu overexpression and intestinal
phenotype) may be expressed together preferentially. In the Finnish
study, amplification of HER-2/neu was strongly associated with poor
carcinoma-specific survival, particularly evident in the subgroup of
intestinal type of cancers (P =0.0019), which is usually considered to
associate with more favorable prognosis than the diffuse type of gastric
adenocarcinoma.
Independent risk factors of nodal metastasis include the depth of
submucosal invasion, tumor diameter greater than 3.0-3.5 cm, the
presence of lymphovascular permeation, depressed or ulcerated lesions,
and undifferentiated histology. There was no correlation between HER-
2/neu and these factors.
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 The role of HER-2/neu as a prognostic factor in gastric cancer has
been controversial because some of the initial studies failed to find its
association with prognosis.
TREATMENT OF GASTRIC CANCER:-
Surgery is the main modality of treatment. Radical surgery is not
feasible as the disease is locally advanced with adjacent organ infiltration
most of the times. In patients who undergo radical surgery recurrence can
be reduced by giving adjuvant chemotherapy.
The goal is improvement in overall survival and to prevent
recurrence. Meta-analysis of adjuvant chemotherapy by Wagner et al (43)
included 13 trials with a total of 1,990 patients. The absolute risk
reduction using chemotherapy was estimated to be 4%. The median
survival was improved from 4.3 months for best supportive care to
approximately 11 months for chemotherapy. There was also a modest
improvement in time to progression from 7 months for patients receiving
chemotherapy and 2.5 months for patients receiving best supportive care.
Wagner et al concluded that the evidence supporting initiating
chemotherapy for patients with advanced incurable gastric cancer was
convincing.
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 Mari et al(44) recently reported the results of a meta-analysis of 20
individual clinical trials. A total of 3,650 patients were involved. Seven
of these trials included the use of fluorouracil plus an anthracycline. They
concluded that there was a small survival benefit.
Moertel et al (45) reported the results of a small randomized trial of
radiation therapy (3,750 cGy in 24 fractions) plus 5-FU (15 mg/kg in
three doses) versus surgery alone arm. A statistical assessment was done
on the local, distant relapse, and overall survival of these patients. These
data suggest that the primary effect of postoperative chemoradiation
treatment was a reduction in local recurrence rates without apparent
differences in distant relapse rates and survival.
Platinum compounds are an important part of treatment of gastric
cancer. The use of cisplatin, in both previously treated and untreated
patients, showed a response rate of approximately 15%. With 5
flurouracil overall response rates were 10% to 20%, with a median
duration of response, or time to progression, of approximately 4 months.
A third class of cytotoxic agents with activity in gastric cancer is the
Taxanes. Docetaxel has been more extensively studied. In a recent
review, Cosimo (46) reviewed trials in which docetaxel was used as single
agent and the response rate was 19.1%.
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 Importantly, in those best supportive care trials that reported 2-year
survival only patients who received chemotherapy survived. The 2-year
survival rate was 5% to 14% for patients receiving combination
chemotherapy versus 0% for patients receiving best supportive care. The
results of these studies and supportive evidence from more recent trials
indicate that fit patients with advanced incurable gastric cancer who can
tolerate potential toxicities have a modest but real benefit with
chemotherapy in survival when compared to best supportive care.
Targeting HER-2 in gastric cancer
The Her-2/neu gene encodes a 185-kDa transmembrane
glycoprotein, possessing intrinsic protein tyrosine kinase activity.(51)
HER-2/neu overexpression is increasingly recognized as a frequent
molecular abnormality, driven as in gastric cancer by gene amplification.
It has been solidly correlated to poor outcomes and a more aggressive
disease. Additionally, preclinical data with invitro and invivo models are
showing significant antitumor efficacy of anti-HER-2/neu therapies
(particularly monoclonal antibodies directed towards the protein). As a
result, several clinical trials are exploring in different settings and with
diverse designs the potential of anti- HER-2/neu therapies in patients
with gastric cancer.
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TRASTUZUMAB (47)
Trastuzumab is a recombinant humanized anti-HER-2/neu
monoclonal antibody directed against the HER-2/neu extracelluar
domain. The antibody was humanized to minimize the immunogenicity
associated with murine monoclonal antibody and to enhance endogenous
immune antitumor effects. Its exact mechanism of action is not
completely known, however extracellular and intracellular actions have
been postulated.
Extracellular Mechanisms
1. Blocks HER-2/neu receptor cleavage and inhibits dimerization
consequently reducing HER-2/neu signaling.
2. Increases receptor destruction by endocytosis. Trastuzumab seems
to induce HER-2/neu down regulation and subsequent degradation
in HER-2/neu over-expressing cancer cells.
Intracellular Mechanisms:
1. Inhibits intracellular signaling pathways, such as phosphoinositide
3-kinase (PI3K) signaling.
2. Has anti-angiogenesis effect through decreasing vascular
endothelial growth factor (VEGF) produced by tumor cells; it may
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indirectlymodulate proangiogenic and antiangiogenic factors, and
also has synergistic activity with chemotherapy.
3. By inducing cyclin-dependent (CDK) inhibitor p27 Facilitates G1
phase arrest.
4. Has Cytotoxic and Cytostatic activity due to immune system
recruitment by antibody-dependent cell-mediated cytotoxicity
(ADCC).
Trastuzumab was used along with chemotherapy in clinical trials
and has proven to increase the survival of patients with metastatic gastric
cancer. ToGA (Trastuzumab for Gastric Cancer ) was a phase 3, open-
label, international, randomised controlled trial. Patients eligible for
inclusion had gastric or gastro – oesophageal junction cancer and if their
tumours showed gene amplification by fluorescence insitu hybridisation
or overexpression of HER-2/neu protein by immunohistochemistry.
Participants were randomly assigned in a 1:1 ratio to receive a
chemotherapy regimen consisting of cisplatin plus capecitabine or
5 fluorouracil plus cisplatin alone or chemotherapy in combination with
intravenous trastuzumab given every 3 weeks for six cycles.
Capecitabine was given at a dose of 1000 mg/sq.m orally twice a
day for 14 days followed by a 1-week rest, or fluorouracil 800 mg/sq.m
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per day was given by continuous intravenous infusion on days 1-5 of
each cycle. Cisplatin at a dose of 80 mg/sq.m on day 1 was given by
intravenous infusion. Trastuzumab was given on day 1 of the first cycle
by intravenous infusion at a dose of 8 mg/kg, followed by 6 mg/kg every
3 weeks until, unacceptable toxicity, disease progression or withdrawal
of consent.
Median overall survival in patients assigned to trastuzumab plus
chemotherapy was 13.8 months compared with 11.1(48) months in those
assigned to chemotherapy alone, corresponding to reduction in the death
rate by 26%. Confirmatory analysis that included all 594 randomised
patients provided consistent results. The survival benefit was most
evident in patients with high levels of HER-2/neu over -expression ,that
is whose tumor was FISH+ or IHC 3+ ,with median overall survival of
16.0 vs 11.8 months for patients with high and low levels of HER-2/neu
expression. “For gastric cancer, this was probably one of the largest
differences we have seen in overall survival with the addition of just one
agent in the recent decades.
The adverse event profile was similar in both the groups. There
was no difference between both groups in frequency of grade 3 or 4
adverse events apart from diarrhoea. Cardiac adverse events was seen
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only in 6% of patients with no difference between the trastuzumab plus
chemotherapy and chemotherapy alone groups.
Establishing the HER-2/neu status in advanced gastric cancers and
in OG junction cancers has become a routine diagnostic histopathological
investigation. After TOGA trial combination of Trastuzumab with
Cisplatin and 5FU doublet is now a standard treatment options for
gastric carcinoma patients with HER-2/neu positivity.. FDA has
approved Trastuzumab use in patients with Her-2/neu positive carcinoma
stomach patients. In addition to Herceptin, Lapatinib is also being
investigated in patients with HER-2/neu positive gastric cancer. LOGIC,
a phase III clinical trial in which Lapatinib is being used along with
Oxaliplatin and Capecitabine is ongoing. sIn a Phase II trial it showed a
median survival of 5 months with an overall response rate of 9%. The
TYTAN trial is an ongoing trial evaluating Lapatinib with Paclitaxel in
second line setting.
At present, the most common method to assess HER-2/neu
overexpression is IHC, which is a technique available in most pathology
laboratories to detect protein expression levels. Since the costs for
trastuzumab therapy are high and side effects are minimal, accurate
selection of patients for this therapy is useful in prolonging survival for
desired patients.
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AIM OF THE STUDY
The aim of this study:
1) To assess HER-2/neu overexpression in gastric carcinoma patients
2) To assess the correlation between HER-2/neu overexpression and
clinico-pathologic characteristics.
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MATERIALSAND METHODS 
The present study is a Prospective study conducted in the
Department of Medical Oncology, Madras Medical College and Rajiv
Gandhi Government General Hospital for a period of one year between
January 2011 and December 2011. Informed written consent was
obtained from all patients prior to the start of the study. Institutional
Ethics committee approval was obtained at the start of the study. 
Inclusion criteria:
1. Patients aged 18-65 years with gastric carcinoma proven by
histopathology.
2. Adenocarcinoma by histology. 
Exclusion criteria:
Histologies other than adneocarcinoma. 
METHODS
 All selected patients underwent diagnostic upper gastrointestinal
endoscopy. A CT scan of abdomen was done for all patients as staging
procedure. The AJCC TNM cancer staging 7th edition was used for
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IHC- NEGATIVE
 
 
IHC – SCORE 1+
 
staging.Of the 50 samples evaluated, 25 were endoscopic specimens and
25 were post gastrectomy specimens.  
IHC EVALUATION 
 IHC evaluation of HER-2/neu was done in paraffin embedded
tissue samples using Super Sensitive polymer HPR system based on non-
biotic polymeric technology. Four micron thick sections from formalin
fixed paraffin embedded tissue samples were transferred on to gelatin
coated slides. Antigen retrieval was done using the heating method
(microwave).The antigen was bound with mouse monoclonal antibody
(Biogenex) against HER-2/neu and then detected by addition of
secondary antibody conjugated with horse radish peroxidase-polymer and
Diaminobenzidine subtrate.
STEPS IN IHC
1. Four micron thin sections cut from formalin fixed paraffin
embedded tissue samples and transferred to gelatin chrome alum
coated slides. 
2. Slides incubated at fifty eight degrees overnight. 
3. Sections deparrafined in xylene twice for fifteen minutes each
time.
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 4. Sections washed dehydrated with absolute alcohol for five
minutes twice. 
5. Sections washed with tap water for ten minutes. 
6. Slides immersed in distilled water for five minutes. 
7. Heat induced antigen retrieval done with microwave oven in
appropriate temperature with citrate buffer for twenty to twenty
five minutes. 
8. Slides rinsed in distilled water for five minutes. 
9. Slides cooled to room temperature and washed with running tap
water for five minutes. 
10. Washed with phosphate buffer twice for five minutes each time. 
11. Application of peroxidase block over section for ten minutes. 
12. Slides washed in phosphate buffer twice for five minutes each
time. 
13. Sections covered with power block for fifteen minutes. 
14. Sections drained without washing and primary antibody applied
over sections and incubated for one hour at room temperature. 
15. Slides covered with super enhancer for thirty minutes. 
16. Slides washed in phosphate buffer twice for five minutes. 
17. Slides covered with super sensitive label for thirty minutes. 
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18. Slides washed with phosphate buffer twice for five minutes. 
19. Diaminobenzidine substrate freshly prepared by diluting one
drop of DAB chromogen with one milliliter of DAB buffer. 
20. DAB substrate solution applied on to sections for eight minutes. 
21. Washed with phosphate buffer twice for five minutes each time. 
22. Slides washed in running tap water for five minutes. 
23. Sections counter stained with hematoxylin stain for two seconds. 
24. Slides washed in running tap water for three minutes.
25. Slides air dried, cleared with xylene and mounted with DPX.
Reporting was done using Hoffman Score
Results were tabulated in an excel sheet and data was analysed
using SPSS Version 17.0 and chi-square 2 tail test was used and ‘P’
value of less than 0.05 was considered to be statistically significant.
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RESULTSAND ANALYSIS OF OBSERVED DATA
A total of 50 patients were included in this study. Various
clinicopathologic characteristic features like age, sex, histopathological
type and grade were analysed for association with Her-2/neu gene
overexpression.
IHC SCORE
Out of 50 patients, 10 (20%) were 3+, 3 patients (6%) had 2+, 10
patients (20%) had 1+ and 27 patients (54%) had 0 score by IHC.
AGE DISTRIBUTION
Most of the patients were above 50 years of age (n=33,66%) and
22 patients below 50 years of age (34%). The mean age of the study
population was 52 + 10 years (range 32-72 years). There was no
difference in the age at presentation in HER-2/neu positive and negative
patients.(p=0.941)
AGE DISTRIBUTION OF PATIENTS
HER 2 N Mean Std. Dev P-Value
Negative 40 52.43 10.507Age
(years)
Positive 10 52.70 10.328
0.941
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SEX DISTRIBUTION
In the present study, 33 were males (66%) and 17 were females
(34%.). The Male: Female ratio was 2:1. When further analysis was done
we found that in both HER-2/neu positive and negative patients, males
contributed to two thirds of the disease population and females
contributed to one third of patients. This indicates that there was no sex
prediliction for HER-2/neu gene.
SEX DISTRIBUTION OF PATIENTS
HER 2
Negative Positive
Total
Gender
N % N % N %
P-Value
Male 26 65.0 7 70.0 33 66.0
Female 14 35.0 3 30.0 17 34.0
Total 40 100.0 10 100.0 50 100.0
0.997
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SYMTOMATOLOGY
Analysis was done to determine whether there was any difference
in the chief complaints of the patient between HER-2/neu positive and
negative patients. The duration of symptoms was between three to six
months irrespective of the HER-2/neu status. The most common
complaint was abdominal pain and associated weight loss in 22 patients
(44%), 16 patients (32%) had presented to us with abdominal pain alone
as their chief complaint and 11 (22%) patients had presented with
vomiting and weight loss. One patient (2%) had presented with vomiting
alone as the chief symptom, he was found to have features of acute
intestinal obstruction and underwent surgery immediately. This patient
was negative for HER-2/neu overexpression. HER-2/neu gene positive
patients did not have any specific symptom due to its overexpression.
SYMPTOMS
HER 2
Negative Positive
Total
Complaint
N % N % N %
P-Value
Pain 12 30.0 4 40.0 16 32.0
Pain,
Weight loss 17 42.5 5 50.0 22 44.0
Vomiting ,
Weight loss 10 25.0 1 10.0 11 22.0
Vomiting 1 2.5 0 0.0 1 2.0
Total 40 100.0 10 100.0 50 100.0
0.701
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ENDOSCOPY
All patients underwent endoscopy. .At endoscopy, 30(60%)
patients had antral involvement and 20 (40%) had lesion in the body of
the stomach .Though HER-2/neu positive patients had prediliction
towards antral region when compared to the negative population, the P
value was not significant (P=0.279). All (100%) patients had
proliferative type of growth.
SITE OF LESION IN ENDOSCOPY
HER 2
Negative Positive
Total
Endoscopy site
N % N % N %
P-Value
Antrum 22 55.0 8 80.0 30 60.0
Body 18 45.0 2 20.0 20 40.0
Total 40 100.0 10 100.0 50 100.0
0.279
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GRADEOF THE TUMOR
Analysis was done to determine whether HER-2/neu positivity was
associated with the grade of tumor. Fifty two percent of the patients had
poorly differentiated carcinoma, 30% had moderately differentiated
carcinoma and 18% had well differentiated carcinoma. In HER-2/neu
positive subgroup 50% had poorly differentiated grade, 40% with
moderately differentiated grade and only 10 % were well differentiated
grade. In HER-2/neu negative group 52% had poorly differentiated grade,
28% had moderately differentiated grade and 20% had well differentiated
grade. There was no significant difference in grade of tumor between
HER-2/neu positive and negative tumors.(P=0.647)
HER 2
Negative Positive
Total
HPE grade
N % N % N %
P-Value
Well differentiated 8 20.0 1 10.0 9 18.0
Moderately
differentiated 11 27.5 4 40.0 15 30.0
Poorly differentiated 21 52.5 5 50.0 26 52.0
Total 40 100.0 10 100.0 50 100.0
0.647
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LAURENSTYPE OF TUMOR
Analysis was done to find out the association between HER-2/neu
positivity and any particular pathological type in Laurens classification.
It was observed that 38 patients (76%) had intestinal type of cancer and
12 patients (24%) had diffuse type of cancer. All 10 patients with HER-
2/neu positivity had only intestinal type of cancer. In the HER-2/neu
negative group, 28 patients(70%) had intestinal type of cancer and 12
patients(30%) had diffuse type of cancer. Although HER-2/neu positivity
was strongly associated with intestinal type of tumor, it did not differ
significantly from the Her 2 negative group.(P=0.116)
HER 2
Negative Positive
Total
I / D
N % N % N %
P-Value
Diffuse 12 30.0 0 0.0 12 24.0
Intestinal 28 70.0 10 100.0 38 76.0
Total 40 100.0 10 100.0 50 100.0
0.116
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CTABDOMEN
NODAL ASSESSMENT BY IMAGING
All patients underwent CT abdomen as part of staging workup and
to assess the feasibility of surgery. The Pyloric, Gastroduodenal,
Gastroepiploic, Splenic, Pancreaticoduodenal, Peripancreatic,Right
gastric,Left gastric, hepatoduodenal, celiac and common hepatic nodes
were considered as regional nodes. Presence of Portal, Para aortic,
Retroperitoneal, Retropancreatic and Mesentric nodes was considered to
be metastatic disease.
On imaging, 26 patients (52%) had regional nodes and 24 patients
(48%) did not have nodal involvement. Nodes were present in 40% of
HER-2/neu negative patients. Though 60 % of HER-2/neu positive
patients had nodes, the difference between them was not statistically
significant.(p=0.620)
PRESENCE OF NODE BY IMAGING
HER 2
Negative Positive
TotalCT Nodes
N % N % N %
P-Value
Absent 22 55.0 4 40.0 26 52.0
Present 18 45.0 6 60.0 24 48.0
Total 40 100.0 10 100.0 50 100.0
0.620
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ASCITES
Correlation between presence of HER-2/neu positivity and
presence or absence of ascites was analysed. Ascites was present in 13
patients (26%) and absent in 37 patients(74%). Patients with ascites were
inoperable at diagnosis itself and were considered only for palliative
treatment. None the patients with ascites had HER-2/neu positivity.
HER 2
Negative Positive
Total
CT ascites
N % N % N %
P-Value
Absent 27 67.5 10 100.0 37 74.0
Present 13 32.5 0 0.0 13 26.0
Total 40 100.0 10 100.0 50 100.0
0.091
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ADJACENTORGAN INVOLVEMENT
Twenty patients(40%) had adjacent organ infiltration . Most
patients had posterior infiltration in to pancreas. The other organs
involved were duodenum , transverse colon, and splenic flexure. Forty
percent of patients in both HER-2/neu positive and negative group had
adjacent organ infiltration. There was no correlation between HER-2/neu
positivity and T stage of the disease.
ADJACENT ORGAN INVOLVEMENT BY IMAGING
HER 2
Negative Positive
TotalCT adjacent
organ
infiltration
N % N % %
P-Value
Absent 24 60.0 6 60.0 30 60.0
Present 16 40.0 4 40.0 20 40.0
Total 40 100.0 10 100.0 50 100.0
1.000
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OMENTALDEPOSITS
Out of fifty patients, eight patients (16%) had Omental deposits on
imaging and 42 patients (84%) did not have omental deposits. none of the
HER-2/neu positive patients had omental deposit.
OMENTAL DEPOSIT BY IMAGING
HER 2
Negative Positive
TotalCT
Omental
deposits
N % N % N %
P-Value
Absent 32 80.0 10 100.0 42 84.0
Present 8 20.0 0 0.0 8 16.0
Total 40 100.0 10 100.0 50 100.0
0.289
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LIVERSECONDARIES BY IMAGING
Liver secondaries were seen in 13 patients (26%). Liver
secondaries were seen in 30% of HER-2/neu negative and10% of
HER-2/neu positive patients. There was no significant correlation
between HER-2/neu and presence of liver secondaries.
LIVER SECONDARIES BY IMAGING
HER 2
Negative Positive
TotalCT liver
secondaries
N % N % N %
P-Value
Absent 28 70.0 9 90.0 37 74.0
Present 12 30.0 1 10.0 13 26.0
Total 40 100.0 10 100.0 50 100.0
0.375
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SURGERY
Depending on the stage of the disease and the site of the disease 31
(62%) patients underwent various type of surgeries as follows
Types of Surgery
1. Subtotal gastrectomy
2. Total gastrectomy
3. Anterior gastrojejunostomy
4. Distal gastrectomy
5. Feeding jejunostomy
Radical surgery was done for 28% of HER-2/neu negative and
50% of HER-2/neu positive patients.
HER 2
Negative Positive
TotalPalliative/
Radical
N % N % N %
P-Value
Palliative 15 72.0 3 50.0 18 67.7
Radical 4 28.0 3 50.0 7 32.3
Total 19 100.0 6 100.0 25 100.0
0.583
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SIZEOF THE TUMOR
Analysis was done to see for correlation between size of the tumor
and HER-2/neu Overexpression .Tumor size was less than three cm in
one patient (4%) who was HER-2/neu negative. Fifteen patients (57%)
had tumor size of 3-6 cms. Fifty percent of HER-2/neu positive patients
and 60% in HER 2 negative patients had 3 to 6 centimeter tumor. Ten
patients(39%) had tumor more than 6 centimeter. Thirty five percent of
HER-2/neu negative and 5o% of HER-2/neu positive population had
tumor size >6 centimeter. Though HER-2/neu positive patients had larger
tumor size, it was not statistically significant.(p=0.650)
SIZE OF THE TUMOR
HER 2
Negative Positive
TotalHistopathology
size
N % N % N %
P-Value
< 3 cm 1 5.0 0 0.0 1 3.8
3 - 6 cm 11 60.0 3 50.0 14 57.7
> 6 cm 7 35.0 3 50.0 10 38.5
Total 20 100.0 6 100.0 25 100.0
0.650
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‘T’STAGE
Tumor stage was assessed using the AJCC TNM 7th edition. Two
patients (8%) had T2 disease and they were found to be HER-2/neu
negative. Fifteen patients (54%) had T3 disease . T3 disease was seen in
50% in HER-2/neu negative and 66% in HER-2/neu positive patients.
Out of 11 patients (38%) who had T4 disease, 34% were HER-2/neu
positive and 41% were HER-2/neu negative.
‘T’ STAGE BY HPE
HER 2
Negative Positive
Total
T-Stage
N % N % N %
P-Value
T-2 2 9.1 0 0.0 2 8
T-3 11 50.0 4 66.7 15 54
T-4 9 40.9 2 33.3 11 38
Total 22 100.0 6 100.0 28 100.0
0.651
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LYMPHOVASCULARINVASION
It was observed that 18 out of 25 patients who underwent radical
surgery (72%) had lymphovascular invasion. Lymphovascular invasion
was seen in 83% of HER-2/neu positive and 69% of HER-2/neu
negative patients.There was no statistically significant difference
between both groups.(P=0.851)
LYMPHOVASCULAR INVASION
HER 2
Negative Positive
TotalLymphovascular
invasion
N % N % N %
P-Value
No 6 31.6 1 16.7 7 28.0
Yes 13 68.4 5 83.3 18 72.0
Total 19 100.0 6 100.0 25 100.0
0.851
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PERINEURALINVASION
Analysis for presence or absence of perineural invasion was done
in relation to HER-2/neu overexpression. Fourteen out of 25 patients
(56%) had perineural invasion and 11 patients (44%) had no perineural
invasion .Perineural invasion was found in 50% of HER-2/neu positive
group and in 58% of HER-2/neu negative subgroup and there was no
significant difference in both the groups.(P=0.997)
HER 2
Negative Positive
TotalPerineural
Invasion
N % N % N %
P-Value
No 8 42.1 3 50.0 11 44.0
Yes 11 57.9 3 50.0 14 56.0
Total 19 100.0 6 100.0 25 100.0
0.997
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METASTASIS
Out of 50 patients, 20 (40%) had metastatic disease at presentation.
The most common sites of metastasis were peritoneum, omentum and
liver parenchyma. The incidence of metastatic diseases was 40% of
patients in both the subgroups and was not significantly different.
(P=1)
HER 2
Negative Positive
Total
Metastasis
N % N % N %
P-Value
No 24 60.0 6 60.0 30 60.0
Yes 16 40.0 4 40.0 20 40.0
Total 40 100.0 10 100.0 50 100.0
1.000
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DISCUSSION
Gastric carcinoma is one among the top five causes of cancer in both
males and females. It is also listed among the top cancer related
mortalities. Despite the advancements in the treatment of gastric cancer,
none has shown to improve the survival significantly. There was no
additional improvement in overall survival with addition of Epirubicin or
Docetaxol to Cisplatin and 5FU combinations although the response rate
was better. The role of targeted therapy has recently come into play after
the establishment of the role of HER-2/neu over-expression in gastric
malignancies. Trastuzumab ,an anti HER-2/neu antibody ,in combination
with Cisplatin and 5FU in advanced gastric carcinoma patients has
shown to improve overall survival in TOGA trial This study was
undertaken to find out the prevalence and the clinicopathological
correlation in HER-2/neu over –expression in gastric carcinoma patients.
Most of the observations made in this study correlated well with
the world literature. The prevalence of HER-2/neu over-expression in this
study population was 20%, which correlated well with other studies.
(8-27%).
The age of the patients at diagnosis in this study ranged between
35-75 with 66% more than 50 years of age. This was in contradiction to
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SEER data in 2010 which states the mean age at diagnosis of gastric
cancer is around 70 years. Our patients were diagnosed at much earlier
age .According to SEER data only 17% were below 50 years of age .in
the present study, 34% presented at an earlier age .The etiological and
epidemiological factors leading to such drastic difference at presentation
needs to be analysed. There was no difference in age at presentation
between HER-2/neu positive and negative patients. This observation was
similar to the studies made by YQ and Cai X et al.
There was a strong male preponderance for gastric cancer, with a 2:1
ratio of male: female. This was similar to the data by SEER in 2010
which showed the incidence of gastric carcinoma in males to around 64%
and females around 36%. Antral region was commonly involved and this
is in concordance with the study by Hermann RE et al.
When analysis was done for the significance of grade in relation
to HER-2/neu status we found that 25 (50%) of our patients had poorly
differentiated carcinoma. When subset analysis was done 50% of them
were HER-2/neu positive and 50% HER-2/neu negative. When analysis
was done only in HER-2/neu positive population, 50% had poorly
differentiated grade and 30% moderately differentiated grade and 20%
well differentiated grade. This was similar to analysis done by park et al.
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 CT abdomen was done in all our patients and we had analysed the
presence of nodes by imaging, adjacent organ infiltration, liver
secondaries and omental deposits .When comparison was done between
HER-2/neu positive and negative patients there was no difference
between the two groups. There was no correlation between TNM staging
and HER-2/neu positivity. This was similar to the study by Gravalos C,
Marquez A, Garcıa-Carbonero R et al.
The type of surgery done was analysed to determine whether
radical procedure could be done in HER-2/neu positive patients. There
was no difference between HER-2/neu positive and negative patients
.Radical surgery was feasible in 50% of HER-2/neu positive patients and
only 28% of HER 2 neu negative patients underwent radical surgery.
This clearly states that HER-2/neu positvity is not aggressive at
presentation. Tanner, M. Hollm ´en, T. T. Junttila et al. also observed
similar findings in their study.
The Lauren pathological type of tumor and its association with
HER-2/neu was looked in to. All our HER-2/neu patients had only
intestinal type of tumor . This was similar to studies by Nakajima, et al,
Park, et al. and Tanner, et al .The reason for association of HER-2/neu
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withintestinal type of cancer has to be investigated further to identify the
cause of this association and prevent if feasible. The ideal algorithm for
testing HER-2/neu is
We had 3 patients with equivocal result by IHC .This analysis had
the lacuna of not analyzing these equivocal cases by FISH .This was due
to the lack of availability of FISH in our institution.
The present study showed that there was no clinicopathological
correlation between HER-2/neu positivity and age, sex, presenting
complaints, site of lesion, grade of tumor, TNM staging. This indicates
that HER-2/neu may be an independent prognostic marker. When
overexpressed, it predicts the response to Trastuzumab. Thus, it is the
first predictive factor available for gastric cancer and all gastric
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carcinoma patients should undergo HER-2/neu testing to obtain its
benefit. More centers should be equipped with the availability of IHC
facility . Pathologists should to be trained to interpret HER-2/neu in
gastric cancer as it is different from interpreting breast cancer.
Trastuzumab in combination with chemotherapy is now considered
to be a new standard of care for patients with HER-2/neu positive
advanced gastric or esophagogastric junction adenocarcinoma. The
current recommended treatment of gastric cancer is
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 Trials are underway to test the benefit of Trastuzumab in adjuvant
and neoadjuvant setting to extend its benefit Further important questions
such as duration of treatment, its safety in combination with other
regimens like ECF, remains to be determined Trials evaluating
Trastuzumab beyond disease progression, and also in pre treated gastric
cancer patients to improve their outcome.
Lapatinb, which blocks both HER-1 and HER-2/neu works
synergistically with Trastuzumab in. Preclinical studies in gastric cancer
cell lines. This is also being looked in to .Also ongoing projects are
using Pertuzumab which prevents HER-2/neu dimerization, is being used
along with Trastuzumab to increase the benefit. Extended HER-2/neu
blockade with enhanced antitumor efficacy makes this combination
possible and should be evaluated without delay. Cross-talk between
HER-2/neu and other EGFR family members is likely to contribute to
trastuzumab resistance.
Highly-selective, small molecule pan-HER inhibitors have the
potential to improve antitumor activity and ability to over-come
trastuzumab resistance. Strategies to overcome resistance to trastuzumab
are being investigated rapidly to improve the survival of gastric cancer
patients. As there is clear evidence that Trastuzumab has improved
overall survival when given along with cisplatin and 5 fu and since there
56
are no major side effects with Trastuzumab, it is ideal that all patients
with gastric carcinoma are tested for HER-2/neu and be given the benefit
of it. The laboratories in the hospital should be well equipped with
availability both IHC and FISH to test HER-2/neu gene. Patients may
develop pimary and acquired resistance to Trastuzumab due to crosstalk
between pathways. Research should also be done with combination of
targeted therapies to overcome this resistance to improve the outcome of
these patients. Beyond all, only a quarter of gastric cancer patients will
have amplification of HER-2/neu gene leaving behind the rest 75% of
patients without any benefit. Therefore it is time to concentrate on these
patients and find out an effective chemotherapeutic or targeting agents
which can really change the outcome of gastric cancer treatment. Also
more trials are necessary in adjuvant setup to improve the disease free
survival in patients who presented at an early stage though equal
importance has to be given to prolong the progression free survival of
patients who present in advanced disease. Each country should try to
identify if any epidemiological factors are influencing the cause and take
steps to get rid of those causative agent which will enable us to decrease
the incidence of this disease.
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SUMMARY
The study titled “Evaluation of HER-2/neu status in Gastric
Carcinoma” was a prospective study of 50 patients with newly diagnosed
Gastric Carcinoma, admitted in the Department of Medical Oncology,
Rajiv Gandhi Government General Hospital, Chennai. Eligible patients
underwent clinical examination, endoscopy, CT Abdomen and Surgery if
feasible. All patients underwent HER-2/neu status assessed in the
histopathological specimen obtained by endoscopic biopsy or post
gastrectomy specimen. The correlation between HER-2/neu status
overexpression and clinicopathological features was analysed. There was
no significant association between HER-2/neu status and
clinicopathological features.
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CONCLUSION
The following conclusions were made from this study
• Patients in this study presented at younger age than quoted in the
western population. 
• The prevalence of HER-2/neu overexpression was 20% in this
study population. 
• HER-2/neu overexpression was not associated with any major
clinical or pathological features. 
• Since targeting HER-2/neu has shown an overall survival benefit of
2.7 months in literature, it can be recommended that all patients
with newly diagnosed gastric cancer should undergo HER-2/neu
testing for subsequent treatment with anti HER-2/neu therapy.
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Evaluation of HER-2/neu status in Gastric Carcinoma
ABSTRACT
INTRODUCTION
Gastric carcinoma is the fourth most commonly diagnosed cancer in the
world and is the second leading cause of cancer related death. More than 50% of
patients with gastric cancer present in advanced, unresectable stages, making
cure impossible. Two-thirds of these patients who undergo radical surgery will
experience. Systemic treatment is the only option for the patients presenting in
advanced stages. The median survival after diagnosis of metastatic disease is
approximately 10-11 monhs with currently available treatments. Many single
agents and combination chemotherapeutic agents are active in the treatment of
metastatic disease. Objective response rates ranging from 10% to 30% for
single-agent and 30% to 60% for combination regimens have been reported.
The role of targeted therapy has recently come into play after the establishment
of the role of HER-2/neu over-expression in gastric malignancies.
Trastuzumab ,an anti HER-2/neu antibody ,in combination with Cisplatin and
5FU in advanced gastric carcinoma patients has shown to improve overall
survival by 2.7 months in TOGA trial.
This study was undertaken to find out the prevalence and the
clinicopathological correlation in HER-2/neu overexpression in gastric
carcinoma patients.
METHODS
IHC evaluation of HER-2/neu was done in paraffin embedded tissue
samples of 50 gastric carcinoma histopathology specimen. Of the 50 samples
evaluated, 25 were endoscopic specimens and 25 were post gastrectomy
specimens. Immunohistochemistry scoring was done with modified Hoffmann
score. Results were tabulated and analysed for prevalance of HER-2/neu
prevalence and the clinicopathological correlation in HER-2/neu overexpression
in gastric carcinoma patients.
RESULTS
Out of 50 patients, 10 (20%) were 3+, 3 patients (6%) had 2+, 10 patients
(20%) had 1+ and 27 patients (54%) had 0 score by IHC. HER-2/neu
overexpression was not associated with any major clinical or pathological
features like age,sex, TNM staging, type of growth and grade of tumor.
CONCLUSION
The prevalence of HER-2/neu overexpression was 20% in this study population.
Since targeting HER-2/neu has shown an overall survival benefit of 2.7
months in literature, it can be recommended that all patients with newly
diagnosed gastric cancer should undergo HER-2/neu testing for subsequent
treatment with anti HER-2/neu therapy.
KEYWORDS
Carcinoma Stomach, HER-2/neu in CA Stomach, Trastuzumab.
